KEI Staff's blog
Earlier KEI published sections of the the EU India Negotiating FTA/BTIA negotiating text dealing with enforcement, along with some commentary on Article 17-31: http://keionline.org/node/1681.
On March 28, 2013, KEI obtained another document with Article 1-5,7-8,10-33 of the negotiating next. The new text is available at http://keionline.org/node/1691
Krista Cox will be providing her impressions here: http://keionline.org/node/1693
Here are KEI's quick reactions to the text.
Among the provisions in the TRIPS which protect consumers are Article 7, 8 and 40.
On Wednesday, January 23rd, 2013, the Department of State will convene a meeting to discuss a proposal by the Hague Conference on Private International Law ("Hague Conference") to developing a new "instrument" on the recognition and enforcement of judgments, including "new jurisdictional filters."
On March 12, 2012, Tedmund Wan posted a note on Joe Biden's appointment of Steve Ricchetti, exploring potential conflicts of interest with the clients in a lobbying firm that he ran. On March 29, 2012, KEI formally asked Ricchetti to recuse himself in matters concerning his former clients. The letter follows.
29 March 2012
Counselor to Vice President Joe Biden
The White House
Sally Susman of Pfizer leads the most lethal lobbying effort on drug patents and prices. She's also a big Obama campaign fundraiser.
For several years, Pfizer has been considered a hardliner among big pharma companies on international negotiations over intellectual property rights and drug pricing. This has not changed despite the company having had three CEOs in the past five years.
February 22 noon Washington, DC meeting to discuss international negotiations on copyright (With international call-in)Submitted by KEI Staff on 14. February 2012 - 14:12
On Wednesday February 22, 2012, from 12:30pm to 2:30pm, KEI will host a roundtable discussion on international copyright negotiations. The location of the meeting will be 1621 Connecticut Ave, NW, Suite 500, Washington, DC 20009. There will be an opportunity to participate by telephone, via toll free calls in many countries. (To register or for details on call-in, email firstname.lastname@example.org. If you want to try to join by skype, we will do our best.)
The topics to be discussed are the following International copyright negotiations:
KEI files affidavit in India compulsory licensing case involving Bayer patents on cancer drug Sorafenib (Nexavar)Submitted by KEI Staff on 14. February 2012 - 10:05
KEI has provided an affidavit in an India compulsory licensing dispute involving Natco and Bayer, for patents on the cancer drug sorafenib (sold by Bayer under the brand name Nexavar).
The Bayer price for sorafenib/Nexavar in India is $47 per 200 milligram tablet. At a daily dose of 4 tablets, this comes to $5,637 per month, or more than $68 thousand per year. In 2010, per capita income in India was $1,330.
Sangeeta Shashikant from TWN recently collected and published several NGO statements on the Africa IP Summit, in the TWO Info Service on Intellectual Property Issues (Feb12/03), which included a link also to a letter to WIPO signed by more than 100 NGOs.
On February 8, 2012, seven public health organisations submitted a letter to Rep. Darrell Issa (R-CA), Chairman of the Committee on Oversight and Government Reform and the other thirty-nine members of this committee opposing H.R. 3699, the "Research Works Act." This bill, originally introduced on December 16, 2011 by Rep. Issa and Rep. Maloney (D-NY) would prohibit federal agencies from conditioning its federal grants on recipients making its published research results available to the public.
This is a report from the FDA on 2011 new molecular entities (NMEs) approvals, through June 6, 2011. The total number of FDA approvals during that same period was 150. So far, 16 NMEs have been approved in five months, a sharp increase in approvals over the same period 2010.
6 NMEs NDAs were considered priorities
8 NDAs that were considered standard approvals
2 BLA (biologic products) that were not classified.
- NMEs were 10.7 percent of all approvals.
- The NME priority NDAs were 4 percent of FDA approvals.
Confirmation that Obama Administration was "lone hold out" for releasing bracketed ACTA text to the public in Summer of 2010.Submitted by KEI Staff on 25. April 2011 - 15:49
On July 1, 2010, William Yue, the Senior Counsel, Office of the Chief Counsel for International Commerce at the US Department of Commerce, wrote to Joel Blank and John Cobau about the ACTA negotiations. John Cobau was the Chief Counsel for International Commerce at the U.S. Department of Commerce, and Joel Blank was International Attorney-Advisor at US Department of Commerce.
A redacted version of this email was the only document released to KEI as part of a larger FOIA request concerning the Department of Commerce role in the ACTA negotiations. A copy is available here:
Six NGOs, including Knowledge Ecology International (KEI), Medecins Sans Frontieres (MSF), Oxfam, Third World Network (TWN), Universities Allied for Essential Medicines (UAEM), and Young Professionals Chronic Disease Network (YP-CDN), recently submitted recommendations to Member States to control non-communicable diseases (NCDs) in low- and middle-income countries in advance of the Moscow Ministerial conference.
A PDF of the joint statement with logos of the groups is available here:
MEPs Marietje Schaake and Christian Engstrom submit question on appointment of Maria Martin-Prat to EU copyright postSubmitted by KEI Staff on 1. April 2011 - 13:00
The production of generic drugs in India: A new trade agreement with the EU would hinder access to drugs in developing countriesSubmitted by KEI Staff on 23. March 2011 - 5:00
On March 22, 2011, the British Medical Journal (BMJ) published the following guest editorial about the EU/India Free Trade Agreement negotiations.
The following groups and individuals have written to Anand Grover, the Special Rapporteur for the United Nations on the right of everyone to the enjoyment of the highest attainable standard of health, to lodge a complaint about the Trans Pacific Partnership (TPP). The TPP is a regional free trade agreement being negotiated by the governments of Brunei, Chile, New Zealand, Singapore, Australia, Malaysia, Peru, Vietnam and the United States.
KEI has obtained the February 10, 2011 US government draft of the intellectual property chapter of the Trans-Pacific Partnership Agreement (TPP).